Want to take quizzes and track your credits?
In adolescents and young adults without cancer, which opioid prescribing patterns are associated with prescription opioid overdose?
In this claims-based cohort study of 2 752 612 adolescents and young adults without cancer, daily opioid dosage, concurrent benzodiazepine use, and extended-release or long-acting opioid use were associated with increased overdose risk.
The findings suggest that when prescribing opioids to adolescents and young adults, practitioners could potentially mitigate overdose risk by using the lowest effective dosage, avoiding concurrent opioid and benzodiazepine use, and relying on short-acting opioids.
Safe opioid prescribing practices are critical to mitigate the risk of prescription opioid overdose in adolescents and young adults. However, studies that examine opioid prescribing patterns associated with prescription opioid overdose have mostly focused on older adults. The generalizability of these studies to adolescents and young adults is unclear.
To identify opioid prescribing patterns associated with prescription opioid overdose in adolescents and young adults.
Design, Setting, and Participants
This retrospective cohort study assessed privately insured patients aged 12 to 21 years with opioid prescription claims in the IBM MarketScan Commercial Claims and Encounters database between July 1, 2009, and October 1, 2017, and no cancer diagnosis. Data analysis was performed from January 1 to April 30, 2019.
Main Outcomes and Measures
The outcome was a treated opioid overdose as indicated by diagnosis codes. On the basis of days supplied, opioid prescription claims were converted to person-days (the unit of analysis) on which opioid exposure would occur if patients took medications as prescribed. Logistic regression with clustered SEs at the patient level was used to model the occurrence of overdose on a person-day as a function of daily opioid dosage category (<30, 30-59, 60-89, 90-119, or ≥120 morphine milligram equivalents), concurrent benzodiazepine use, and extended-release or long-acting opioid use. Regressions controlled for demographic characteristics, year, opioid use within 180 days, and comorbidities (mental health disorder, substance use disorder, and other chronic condition).
A total of 2 752 612 patients (mean [SD] age at cohort entry, 17.2 [2.5] years; 1 451 918 [52.8%] female) participated in the study. Patients had 4 686 355 opioid prescription claims, corresponding to 21 605 444 person-days. Overdose occurred on 255 person-days among 249 patients (0.01% of the sample). Each increase in daily opioid dosage category was associated with higher overdose risk (adjusted odds ratio [AOR], 1.18; 95% CI, 1.05-1.31). Compared with no use, both concurrent benzodiazepine use (AOR, 1.83; 95% CI, 1.24-2.71) and extended-release or long-acting opioid use (AOR, 2.01; 95% CI, 1.16-3.46) were associated with increased overdose risk.
Conclusions and Relevance
The findings suggest that when prescribing opioids to adolescents and young adults, practitioners could potentially mitigate overdose risk by using the lowest effective daily dosage, avoiding concurrent opioid and benzodiazepine prescribing, and relying on short-acting opioids. Findings are broadly consistent with prior opioid safety studies focused on older adults.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
Accepted for Publication: September 23, 2019.
Corresponding Author: Kao-Ping Chua, MD, PhD, Susan B. Meister Child Health Evaluation and Research Center, Department of Pediatrics, University of Michigan Medical School, 300 N Ingalls St, SPC 5456, Room 6E18, Ann Arbor, MI 48109 (email@example.com).
Published Online: December 16, 2019. doi:10.1001/jamapediatrics.2019.4878
Author Contributions: Dr Chua had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Chua, Brummett, Conti.
Acquisition, analysis, or interpretation of data: Chua, Conti, Bohnert.
Drafting of the manuscript: Chua, Brummett, Conti.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Chua, Conti.
Obtained funding: Chua.
Administrative, technical, or material support: Brummett.
Supervision: Brummett, Conti.
Conflict of Interest Disclosures: Dr Chua reported receiving funding from career development award 1K08DA048110-01 from the National Institute on Drug Abuse. Dr Brummett reported working as a consultant for Heron Therapeutics during the conduct of the study and receiving funding from Recro Pharma Inc, the National Institutes of Health, the Michigan Department of Health and Human Services, National Institute on Drug Abuse, and the UM Michigan Genomics Initiative outside the submitted work. In addition, Dr Brummett had a patent to peripheral perineural dexmedetomidine issued and licensed. No other disclosures were reported.
You currently have no searches saved.